The effect of prior bisphosphonate exposure on the treatment response to teriparatide in clinical practice

Calcified Tissue International

Volumn 81, Issue 5, 2007, Pages 335-340

  Middleton, Edward T ^a   Steel, Sue A ^a   Doherty, Sheelagh M ^a  

^a HULL ROYAL INFIRMARY   (United Kingdom)

Author keywords

Bisphosphonate; Bone mineral density; Bone turnover marker; Osteoporosis; Teriparatide

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; ETIDRONIC ACID; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; PROCOLLAGEN; RISEDRONIC ACID; VITAMIN D;

ADULT; ARTICLE; BONE DENSITY; BONE TURNOVER; CLINICAL PRACTICE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; METABOLIC BONE DISEASE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; FEMUR NECK; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDE FRAGMENTS; PROCOLLAGEN; SPINE; TERIPARATIDE; TREATMENT OUTCOME;

EID: 35948947310     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-007-9066-5     Document Type: Article

References (16)

1. Neer RM, Arnaud CD, Zanchetta JR, et al. (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441
2. Arlot M, Meunier PJ, Boivin G, et al. (2005) Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res 20:1244-1253
3. National Institute for Clinical Excellence (2005) Bisphosphonates (alendronate, etidronate, risedronate), selective oestrogen receptor modulators (raloxifene) and parathyroid hormone (teriparatide) for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. Published appraisals; Technology Appraisal Guidance 87. http://guidance.nice.org.uk/TA87
4. Bone HG, Hosking D, Devogelaer JP, et al. (2004) Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189-1199
5. Ettinger B, San Martin J, Crans G, Pavo I (2004) Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19:745-751
6. Hannon R, Blumsohn A, Naylor K, et al. (1998) Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variation. J Bone Miner Res 13:1124-1133
7. Looker AC, Bauer DC, Chestnut CH, et al. (2000) Clincial use of biochemical markers of bone remodelling: current status and future directions. Osteoporos Int 11:467-480
8. Graham R, Russell G (2007) Determinants of structure-function relationships among bisphosphonates. Bone 40:S21-S25
9. Black DM, Schwartz AV, Ensrud KE, et al. (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-Term Extension (FLEX): a randomized trial. JAMA 296:2927-2938
10. Neele SJ, Evertz R, De Valk-De Roo G, Roos JC, Netelenbos JC (2002) Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women. Bone 30:599-603
11. Black DM, Greenspan SL, Ensrud KE, et al. (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207-1215
12. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM (2003) The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349:1216-1226
13. Boonen S, Marin F, Lyritis G, et al. (2006) Type of prior antiresorptive therapy, but not its duration or washout period, determines the bone mineral density response to 12 months of teriparatide. Calcif Tissue Int 78; Supp1 1:s28, OC012
14. Al-Shahi R, Vousden C, Warlow C (2005) Bias from requiring explicit consent from all participants in observational research: prospective, population based study. BMJ 33:942-945
15. Junghans C, Feder G, Hemingway H, Timmis A, Jones M (2005) Recruiting patients to medical research: double blind randomised trial of "opt-in" versus "opt-out" strategies. BMJ 331:940-942
16. Sheperd JA, Fan B, Lu Y, Lewiecki EM, Miller P, Genant HK (2006) Comparison of BMD precision for Prodigy and Delphi spine and femur scans. Osteoporos Int 17:1303-1308